In September, Hyderabad-based Aurobindo announced that it would acquire the commercial operations of Swiss drug maker Novartis AGsâ generics unit in the US for $900 million. However, the proposed deal, which could emerge as the largest outbound deal by an Indian company, is yet to see the light of day considering that the FTC is yet to respond.
from Moneycontrol Business News https://www.moneycontrol.com/news/business/aurobindoâs-sandoz-deal-may-face-further-delays_12818221.html
In this website you will get all the news regarding about market of various countries and what to be the next prediction or status of market.
Subscribe to:
Post Comments (Atom)
LTIMindtree Q4 Preview: Lower pass-through revenue seen impacting growth marginally
A compilation of estimates suggests the company#39;s Q4 FY24 net profit is projected to decline by 2.2 percent quarter on quarter to Rs 1,1...
-
By BY BEN HUBBARD AND AURELIEN BREEDEN from NYT World https://ift.tt/3oyLkdW >
-
By STEPHANIE SAUL from NYT U.S. https://nyti.ms/2WdcYAk >
No comments:
Post a Comment